Phibro Animal Health Reports Strong Q3 Results, YTD Net Income Jumps 152%, Expands Credit Facility
PAHC has more than doubled off its 52-week low of $18.89.
Summary
Phibro Animal Health Corporation reported strong Q3 and year-to-date fiscal 2026 financial results, with significant growth in net sales and net income, and expanded its revolving credit facility to boost liquidity.
Key Events · Earnings and Guidance · PAHC
-
Strong Q3 & YTD Financial Performance
For the third quarter ended March 31, 2026, net sales increased 10% to $383.5 million, and net income rose 15% to $24.0 million, with diluted EPS at $0.59. Year-to-date, net sales grew 22% to $1,121.3 million, and net income surged 152% to $78.0 million, with diluted EPS at $1.90.
-
Zoetis Acquisition Drives Growth
The acquisition of Zoetis's medicated feed additives portfolio, completed in October 2024, significantly contributed to the Animal Health segment's performance, adding $95.9 million to Q3 net sales and $270.5 million to year-to-date net sales.
-
Expanded Revolving Credit Facility
On April 28, 2026, the company amended its 2024 Credit Agreement to increase its revolving credit commitments by $125 million, from $310 million to $435 million, enhancing operating flexibility and liquidity.
-
Ongoing Regulatory Challenges Noted
The company acknowledged a new Brazilian ordinance, effective April 27, 2026, prohibiting certain performance-enhancing feed additives (virginiamycin and bacitracin), with a 180-day transition period. Phibro is actively seeking therapeutic indications for virginiamycin. Additionally, the company continues to defend its Mecadox product against an FDA withdrawal proposal, with annual sales of approximately $22 million at risk.
Analysis · PAHC · Life Sciences
Phibro Animal Health Corporation delivered robust financial results for the third quarter and first nine months of fiscal 2026, significantly exceeding prior year performance. The substantial year-to-date growth in net income and EPS was largely driven by the successful integration of the Zoetis acquisition, which contributed significantly to the Animal Health segment's sales. The recent expansion of the revolving credit facility further enhances the company's liquidity and operating flexibility. While the company faces ongoing regulatory challenges, particularly the new Brazilian ban on certain performance-enhancing feed additives and the FDA's proposed withdrawal of its Mecadox product, the strong operational performance and improved financial flexibility provide a positive outlook. Investors should continue to monitor the resolution of these regulatory issues and the company's ability to mitigate their impact.
At the time of this filing, PAHC was trading at $57.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $18.89 to $60.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.